



## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number	10/526,406
Filing Date	April 14, 2006
First Named Inventor	Tanuma et al.
Group Art Unit	1646
Examiner Name	Unassigned
Attorney Docket Number	234600
Client Reference No.	201341

Sheet	1	of	1
-------	---	----	---

[illegible][illegible]

OTHER - NON-PATENT LITERATURE DOCUMENTS				
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No+
/JSB/	AC	BLALOCK et al., <i>Biochemical and Biophysical Research Communications</i> , 121(1): 203-207 (May 31, 1984)		
/JSB/	AD	CAMPBELL et al., <i>Microbiol. Immunol.</i> , 46(3): 211-215 (2002)		
/JSB/	AE	FASSINA et al., <i>Archives of Biochemistry and Biophysics</i> , 296(1): 137-143 (July 1992)		
/JSB/	AF	GALLET et al., <i>J. Mol. Biol.</i> , 302: 917-926 (2000)		
/JSB/	AG	GÖBEL et al., <i>Proteins</i> , 18(4): 309-317 (1994)		
/JSB/	AH	MORRIS et al., <i>Journal of Computational Chemistry</i> , 19(14): 1639-1662 (1998)		
/JSB/	AI	OHTAKI et al., <i>Nature</i> , 411: 613-617 (May 31, 2001)		
/JSB/	AJ	ROOT-BERNSTEIN, <i>J. Theor. Biol.</i> , 94: 855-894 (1982)		
/JSB/	AK	TOMII et al., <i>Protein Engineering</i> , 9(1): 27-36 (1996)		
/JSB/	AL	ZHAO et al., <i>The Journal of Immunology</i> , 167: 2130-2141 (2001)		

Examiner Signature	/John S. Brusca/	Date Considered	12/04/2008
--------------------	------------------	-----------------	------------

- \* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).  
 + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).